Ocugen Files 8-K on Feb 21, 2024, for Regulation FD Disclosure

Ticker: OCGN · Form: 8-K · Filed: Feb 21, 2024 · CIK: 1372299

Ocugen, INC. 8-K Filing Summary
FieldDetail
CompanyOcugen, INC. (OCGN)
Form Type8-K
Filed DateFeb 21, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: regulation-fd, disclosure, corporate-filing

TL;DR

**Ocugen just dropped an 8-K, likely sharing important news to keep everyone in the loop!**

AI Summary

Ocugen, Inc. filed an 8-K on February 21, 2024, under Regulation FD Disclosure and Financial Statements and Exhibits. The filing indicates a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934. The company, based in Malvern, Pennsylvania, with IRS Employer Identification Number 04-3522315, is incorporated in Delaware.

Why It Matters

This filing signals that Ocugen, Inc. has disclosed material non-public information, ensuring fair and transparent communication with investors and the public.

Risk Assessment

Risk Level: low — The filing is a standard disclosure and does not inherently indicate a positive or negative event, but rather a regulatory compliance.

Key Players & Entities

FAQ

What is the purpose of Ocugen, Inc.'s 8-K filing on February 21, 2024?

The 8-K filing by Ocugen, Inc. on February 21, 2024, is a Current Report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, specifically under Regulation FD Disclosure and Financial Statements and Exhibits.

When was the earliest event reported in this 8-K filing?

The Date of Earliest Event Reported in this 8-K filing was February 21, 2024.

Where is Ocugen, Inc. incorporated?

Ocugen, Inc. is incorporated in Delaware.

What is Ocugen, Inc.'s Commission File Number?

Ocugen, Inc.'s Commission File Number is 001-36751.

What is the business address of Ocugen, Inc.?

The business address of Ocugen, Inc. is 11 Great Valley Parkway, Malvern, Pennsylvania 19355.

Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-02-21 11:22:29

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Attached as Exhibit 99.1 hereto and incorporated herein by reference is a presentation that Ocugen, Inc. will present at an in-person Clinical Showcase at the Nasdaq Market Site in Times Square, New York City on February 21, 2024, and may use from time to time in presentations or discussions with investors, analysts, and other parties. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. The following exhibits are being furnished herewith: (d) Exhibits Exhibit No. Document 99.1 Ocugen, Inc. Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 21, 2024 OCUGEN, INC. By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing